Michael Makris Shares French Regulatory Update: Marstacimab (Hympavzi) Not Recommended for Severe Haemophilia A or B
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, shared a post on Linkedin:
“Interesting development from France. The French authorities assessed marstacimab (Hympavzi) and concluded that it has no place in the therapeutic strategy for severe haemophilia A or B without inhibitors.
They questioned the robustness of the comparative assessment against other approved therapies and pointed to uncertainties in terms of safety.
The document is in French but Google translate does a pretty good job if you do not speak French. I attach the Google translate version of the conclusion. ”
Check out here for more.
Find more posts on Hemostasis Today.
-
Sep 6, 2026, 16:41Christina (Tina) P.: APS – How it Happens in Your Blood, the Warning Signs, and What to Do about It
-
Sep 6, 2026, 16:33Jose Angel Nicolas Avila: How Tissue Mitochondrial Activity Dictates Macrophage Pool Size
-
Sep 6, 2026, 16:23Kevin Buda: Many High-Risk PE Patients Have Contraindications to Thrombolysis
-
Sep 6, 2026, 16:16Venk Murthy: 2018 vs 2026 ACC/AHA Lipid Guidelines – A Shift From RCTs to Expert Opinion?
-
Sep 6, 2026, 16:11Silmara Montalvão: Improving Global Hemophilia Diagnostics Through Sustained External Quality Assessment
-
Sep 6, 2026, 14:50Mohamed F Doheim: Unraveling the Symphony of Stroke Management
-
Sep 6, 2026, 14:47Ahmed Bennis: E-Cigarette Use and Early Cardiovascular Risk in Young Adults
-
Sep 6, 2026, 14:46William Wallace: Iron Deficiency Can be Present Before Hemoglobin Falls and Before Anemia Appears
-
Sep 6, 2026, 14:15Listening to One Another Drives Innovation and Better Therapies in Hemophilia Care – Global Hemophilia Report